Reed Elsevier PLC
25 August 2006
25 August 2006
ISSUED ON BEHALF OF REED ELSEVIER PLC AND REED ELSEVIER NV
We have today received notification of the following transactions in Reed
Elsevier PLC and Reed Elsevier NV ordinary shares by Mr E Engstrom, a director
of Reed Elsevier PLC and Reed Elsevier NV.
On 23 August 2006 Mr Engstrom exercised a nil cost share award granted to him on
23rd August 2004 over 38,593 Reed Elsevier PLC ordinary shares and 26,677 Reed
Elsevier NV ordinary shares. In order to meet the tax charges arising on the
exercise, Mr Engstrom sold on 24 August 2006 28,367 Reed Elsevier PLC ordinary
shares at 559.5p per share.
On 6 April 2006 Reed Elsevier announced that Mr Engstrom had purchased 7,509
Reed Elsevier PLC American Depositary Shares ('ADRs') (representing 30,036 Reed
Elsevier PLC ordinary shares) at $38.40279 per ADR, under the Reed Elsevier
Group plc Bonus Investment Plan. We have recently been advised that this
information was incorrect and that he purchased 10,030 Reed Elsevier NV ADRs
(representing 20,060 Reed Elsevier NV ordinary shares) at $28.7463 per ADR.
As a consequence of the above, Mr Engstrom's interest in Reed Elsevier shares is
29,479 Reed Elsevier PLC ordinary shares and 73,415 Reed Elsevier NV ordinary
shares.
The ordinary shares required to satisfy the above nil cost award have been
satisfied from the Reed Elsevier Employee Benefit Trust (the 'Trust'). The
Trust is a discretionary employee benefit trust which is operated in conjunction
with Reed Elsevier's share option schemes, and which provides for the transfer
of shares to employees on the exercise of awards granted under the said schemes.
Executive directors of Reed Elsevier PLC and Reed Elsevier NV are, for technical
disclosure purposes, deemed to be interested in the shares held by the Trust, by
virtue of being potential beneficiaries under the Trust.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.